Literature DB >> 24523070

Rational centre selection for RCTs with a parallel economic evaluation--the next step towards increased generalisability?

Adrian Gheorghe1, Tracy Roberts, Thomas D Pinkney, Dion G Morton, Melanie Calvert.   

Abstract

The paper discusses the impact of centre selection on the generalisability of randomised controlled trial (RCT)-based economic evaluations and suggests a future research agenda. The first section briefly reviews the current methods for addressing generalisability. We argue that these methods make no verifiable assumptions about how representative the recruiting centres are to the population of centres in the jurisdiction. The second section uses data from a multicentre RCT to illustrate that cost-effectiveness estimates can be influenced by the sample of recruiting centres. Finally, we propose two concepts that may advance generalisability research. First, we distinguish between the 'research space' and the 'policy space' and argue that policy makers are interested in the latter, while current methods describe the former. Second, we propose a centre-specific generalisability index used at RCT design stage to address generalisability. We conclude that future research should focus on generalisability at RCT design stage rather than on post hoc analyses.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  centre; economic evaluation; generalisability; location; randomised controlled trials

Mesh:

Year:  2014        PMID: 24523070     DOI: 10.1002/hec.3039

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  2 in total

1.  Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index.

Authors:  Adrian Gheorghe; Tracy Roberts; Karla Hemming; Melanie Calvert
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

2.  Design, planning and implementation lessons learnt from a surgical multi-centre randomised controlled trial.

Authors:  Katie Biggs; Daniel Hind; Mike Bradburn; Lizzie Swaby; Steve Brown
Journal:  Trials       Date:  2019-11-01       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.